(Q45233956)

11 December 2017

title

Evidence for use of glatiramer acetate in multiple sclerosis (English)

1 reference

11 December 2017

Zografos Caramanos

1

1 reference

11 December 2017

Douglas L Arnold

series ordinal

2

1 reference

11 December 2017

publication date

1 February 2005

1 reference

11 December 2017

1 reference

11 December 2017

volume

4

1 reference

11 December 2017

issue

2

1 reference

11 December 2017

page(s)

74-5; discussion 76-7

1 reference

Glatiramer acetate for the treatment of multiple sclerosis

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2900974-9

7 January 2021

Lack of evidence for use of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2900974-9

7 January 2021

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2900974-9

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2900974-9

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2900974-9

7 January 2021

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2900974-9

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2900974-9

7 January 2021

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2900974-9

7 January 2021

10.1016/S1474-4422(05)00974-9

Identifiers

DOI

1 reference

11 December 2017

1 reference